<ul><li>Celsius Therapeutics was acquired by AbbVie for $250mn in June 2024</li><li>Amplitude Ventures made an $83mn investment in the company's series B round in 2022</li><li>Celsius had a large dataset from patients in the cancer and inflammatory bowel disease space</li><li>Celsius was developing a TREM1 protein antibody that could reduce symptoms associated with inflammatory bowel disease</li><li>Amplitude backed Celsius due to the previous collaboration with the CSO on other Amplitude portfolio companies</li><li>Celsius required a larger series C round but experienced a difficult time raising capital when the macroeconomic conditions had changed.</li><li>Investors were retrenching and the company was running out of cash.</li><li>A buyer emerged to purchase Celsius for less than its worth, but it decided to sell its TREM1 program to AbbVie instead for $250mn</li><li>Celsius' board set up a transaction committee for a possible financing, partnership, or sale.</li><li>Amplitude played a significant role in the transaction, bringing potential acquirers to the table.</li></ul>

The Path to Exit: How Celsius Therapeutics got acquired by AbbVie

Discover more